

## COVID-19 Research Synergies Meetings

### Therapeutics Session (July 17, 2020)

Time (UTC)	Section	Speakers
12 PM	<b>GloPID-R Welcome &amp; Introduction</b> Opening remarks and introduction of co-chairs	Charu Kaushic, CIHR-III, Canada Yazdan Yazdanpanah, INSERM, France
12:05 PM	<b>Co-Chairs setting the scene: Perspectives on therapeutics research</b>	Glenda Gray, SA MRC Valdiléa Veloso, INI/Fiocruz
12:20 PM	<b>From treating viral infection to other therapeutic avenues: repurposing and new development</b>	
12:20 PM	<b>I. Antiviral treatment</b> 1) Trials in Brazil 2) Effect of Favipiravir to reduce viral load in asymptomatic and mild COVID-19 patients 3) High performance computing for the screening of existing molecules 4) Pre-clinical development of new broad-spectrum antivirals for inhalation 5) Translating pre-clinical experimental data into clinical trials during a pandemic	1) Beatriz Grinsztejn, INI/Fiocruz, Brazil 2) Yohei Doi, Fujita Health University, Japan 3) Andrea Beccari, Dompé Farmaceutici, Italy 4) Anna-Lena Spetz, Stockholm University, Sweden 5) Susanne Herold, Justus-Liebig-University Gießen, Germany
12:45	<b>II. Towards new options for treatment</b> 1) Optimal set of treatments for pandemic infection: How to learn fast 2) Platform trial for immuno-modulators 3) Convalescent plasma 4) Safety and efficacy of SARS-COV2 antibodies 5) Use of anticoagulants	1) Steve Webb, Royal Perth Hospital, Australia 2) Matthieu Resche-Rigon, Université Paris Diderot UFR de Médecine, France 3) Amin Soebandrio, Eijkman Institute, Indonesia 4) Bart Haagmans, Erasmus University Medical Centre Rotterdam 5) Keith Hoots, National Heart, Lung, and Blood Institute, US
13:10	<b>III. Approaches for pre- and post-exposure prophylaxis</b>	Nick White, University of Oxford / Mahidol-Oxford Tropical Medicine Research Unit, Thailand
13:15	<b>IV. Accelerating collaboration for therapeutic interventions</b>	Philippe Duneton, UNITAID

13:20	<b>Panel: Identifying areas of synergy and gaps</b>	Moderated Q&A with panel
13:45	<b>Cross-cutting aspects of therapeutics research</b>	
13:45	<p><b><i>I. Research data sharing</i></b></p> <ol style="list-style-type: none"> <li>1) Pre-clinical &amp; genomics data</li> <li>2) International COVID-19 Data Research Alliance and Workbench</li> <li>3) Challenges for data sharing in low-resource contexts</li> </ol>	<ol style="list-style-type: none"> <li>1) Guy Cochrane, European Bioinformatics Institute, UK</li> <li>2) Steven Kern, Bill &amp; Melinda Gates Foundation</li> <li>3) Ronaldo Ismerio Moreira, Fiocruz, Brazil</li> </ol>
14:00	<p><b><i>II. Clinical trials coordination</i></b></p> <ol style="list-style-type: none"> <li>1) Standard of care definition in low resource settings</li> <li>2) National coordination for clinical trials</li> <li>3) PANDORA: Value of investing in regional preparedness network</li> </ol>	<ol style="list-style-type: none"> <li>1) Greg Calligaro, University of Cape Town Lung Institute, South Africa</li> <li>2) TBC</li> <li>3) Francine Ntoumi, Congolese Foundation for Medical Research, Congo</li> </ol>
14:15	<p><b><i>III. Challenges for therapeutics research</i></b></p> <ol style="list-style-type: none"> <li>1) Barriers encountered</li> <li>2) Community &amp; public involvement</li> </ol>	<ol style="list-style-type: none"> <li>1) Thomas Jaenisch, Heidelberg Institute of Global Health, Germany</li> <li>2) Lisa Schwartz, McMaster University, Canada</li> </ol>
14:25	<p><b><i>IV. Anti-virals for the next epidemic/pandemic</i></b></p>	Johan Neyts, KULeuven, Belgium
14:30	<b>Panel: Identifying areas of synergy and gaps</b>	Moderated Q&A with panel
14:55	<b>Co-chairs' conclusion</b>	Glenda Gray, SA MRC Valdiléa Veloso, INI/Fiocruz